Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Guangzhou Innogen Pharmaceutical Group Co (HKSE:02591) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Guangzhou Innogen Pharmaceutical Group Co Receivables Turnover Related Terms
Guangzhou Innogen Pharmaceutical Group Co Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guangzhou Innogen Pharmaceutical Group Co Receivables Turnover Chart
Guangzhou Innogen Pharmaceutical Group Co Annual Data
Trend
Dec23
Dec24
Dec25
Receivables Turnover
0.00
0.00
23.66
Guangzhou Innogen Pharmaceutical Group Co Semi-Annual Data
Dec23
Jun24
Dec24
Jun25
Dec25
Receivables Turnover
0.00
0.00
0.00
6.56
10.67
HKSE:02591 vs VRTX, REGN, MRNA: Receivables Turnover Comparison
For the Biotechnology subindustry, Guangzhou Innogen Pharmaceutical Group Co's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guangzhou Innogen Pharmaceutical Group Co Receivables Turnover vs Biotechnology Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guangzhou Innogen Pharmaceutical Group Co (HKSE:02591) has a Receivables Turnover of 10.67 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Guangzhou Innogen Pharmaceutical Group Co and its competitors. According to the industry distribution chart, Guangzhou Innogen Pharmaceutical Group Co ranks #87 out of 853 companies in the Biotechnology industry, placing it in the top 10.2%.
Is Guangzhou Innogen Pharmaceutical Group Co's Receivables Turnover too high?
Guangzhou Innogen Pharmaceutical Group Co's current Receivables Turnover is 10.67. The Biotechnology industry median Receivables Turnover is 5.28. Guangzhou Innogen Pharmaceutical Group Co's value of 10.67 is 102.1% above this industry median. Based on the distribution chart, Guangzhou Innogen Pharmaceutical Group Co ranks #87 out of 853 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Guangzhou Innogen Pharmaceutical Group Co has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Guangzhou Innogen Pharmaceutical Group Co's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Guangzhou Innogen Pharmaceutical Group Co ranks #87 out of 853 companies for Receivables Turnover. This places Guangzhou Innogen Pharmaceutical Group Co in the top 10% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.28. Guangzhou Innogen Pharmaceutical Group Co's value of 10.67 is 102.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.28, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Guangzhou Innogen Pharmaceutical Group Co's current Receivables Turnover of 10.67 is 102.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Guangzhou Innogen Pharmaceutical Group Co and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guangzhou Innogen Pharmaceutical Group Co's current Receivables Turnover is 10.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guangzhou Innogen Pharmaceutical Group Co stock overvalued right now?
Guangzhou Innogen Pharmaceutical Group Co (HKSE:02591) has a current Receivables Turnover of 10.67. The current Receivables Turnover is 10.67 and 102.1% above the Biotechnology industry median of 5.28. Guangzhou Innogen Pharmaceutical Group Co's overall GF Score™ is 8/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Guangzhou Innogen Pharmaceutical Group Co (HKSE:02591), the current Receivables Turnover is 10.67 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Guangzhou Innogen Pharmaceutical Group Co Ltd is a company in Asia to commercialize, a humanized, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It has commercialized Efsubaglutide Alfa (brand name: Diabegone), its Core Product, for the treatment of type 2 diabetes (T2D) in China. Its core business model is to discover, develop and commercialize therapies for diabetes and other metabolic diseases. The company has built a pipeline of drug candidates namely YN014, YN401, YN209, YN202,YN203 targeting diabetes and other metabolic diseases.
8GF Score
Get the complete analysis for HKSE:02591
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02591 has been successfully added to your 
